Content Details

Dr. Waqar Younus
MBBS
Information on this page was last modified on : 2024/06/10 7:53:44 PM
Eloctate Antihemophilic factor (Recombinant)Fc fusion protein
- Generic Name: Recombinant
- Drug Strength : 1500IU
- Pack Size : 1 vial
Belongs to CategoryMedicine & Health
How It Works
Eloctate works by replacing the missing or deficient factor VIII in patients with hemophilia A. Factor VIII is crucial for the formation of blood clots, and its absence or deficiency can lead to prolonged bleeding. Eloctate provides the necessary factor VIII, helping to restore the blood’s ability to clot and prevent bleeding episodes.
Side Effects
- Headache
- Nausea
- Joint pain
- Injection site reactions (such as redness, swelling, or itching)
- Increased liver enzymes
Indications
- Prophylaxis to prevent bleeding episodes in patients with hemophilia A
- On-demand treatment of bleeding episodes
- Perioperative management of bleeding in patients with hemophilia A
Contraindications
- Hypersensitivity to any component of Eloctate
- Known allergic reactions to hamster protein
Price Comparison in Different Countries
Country | Price (USD) | Reference |
---|---|---|
United States | $1,500.00 | GoodRx |
United Kingdom | £1,200.00 | NHS UK |
Australia | $2,000.00 AUD | Pharmaceutical Benefits Scheme Australia |
Canada | $1,800.00 CAD | MedBroadcast Canada |
Top 5 Global Brands
- Baxter International
- Biogen
- Pfizer
- Roche
- Sanofi
Additional Information:
One of the following licensed pharmacy from the nearest location will deliver Eloctate Antihemophilic factor (Recombinant)Fc fusion protein. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.
Want to share this information?
Facebook
Twitter
LinkedIn
Something doesn't feel right ?
Questions and Answers
There are no questions yet. Be the first to ask a question about this product.
Only registered users are eligible to enter questions
Reviews
There are no reviews yet.